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Long-term randomized clinical trials of pharmacological treatment
of obesity: Systematic review*
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SUMMARY
Introduction: Obesity has become a public health problem. The increment in energy intake and the reduction of caloric
expenditure as a result of sedentary lifestyles promotes a positive energetic balance resulting in the increase of fat deposits.
In response to this, the prescription of pharmacological treatments has also increased.
Objective: To evaluate the long-term weight loss effectiveness of pharmacological treatments.
Methodology: A systematic review was conducted on randomized clinical trials registered in Pub Med, Scielo, and
EBSCOHOST from January 1st 1999 to December 31st 2008, including those with an intervention program with orlistat,
sibutramine, and rimonabant equal or greater to two years. Two hundred and twelve articles were identified, 201 studies were
excluded, and eleven were analyzed; seven from orlistat, two from sibutramine, and two from rimonabant. Information of design,
intervention time, number of patients, age, body mass index and weight loss, difference between the intervention group versus
the placebo, significance level, and methodological quality were obtained.
Main findings:  The percentage of weight loss with orlistat ranged between 5 and 12%, the mean weight loss was 8 kg,
and a difference between IG vs. placebo of 3.7 kg. Weight loss with sibutramine ranged between 4 and 10%, the mean weight
loss was 7.4 kg and a difference between the intervention group versus placebo was 5.5 kg. Weight loss with rimonabant was
7% with a mean weight loss of 7.3 kg, and the difference compared with the placebo was 4.4 kg.
Conclusions: Weight loss with pharmacotherapy is modest; weight regain after interruption of treatment, adverse effects,
costs and lack of evidence related to long-term morbi-mortality, do not justify the generalized use of pharmacological treatment
of obesity.
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Revisión sistemática de estudios clínicos aleatorios sobre el tratamiento farmacológico a largo plazo para
la obesidad
RESUMEN
Introducción: La obesidad se ha convertido en un problema de salud pública. El incremento en el consumo energético
y el menor gasto calórico, debido al sedentarismo, promueve un balance energético positivo que se traduce en el incremento
de depósitos grasos. En respuesta al incremento de la obesidad se ha aumentado la prescripción del tratamiento farmacológico.
Objetivo: Evaluar la efectividad del tratamiento farmacológico sobre la pérdida de peso con un seguimiento igual o mayor
a 2 años.
Metodologia: Se realizó una revisión sistemática de estudios aleatorios registrados en PubMed, Scielo y EBSCOHOST
del 1 enero de 1999 al 31 de diciembre del 2008 y se seleccionaron aquellos con un período de intervención mayor o igual a
dos años con orlistat (Or), sibutramina (Sib) y rimonabant (Ri). Se identificaron 212 artículos, se excluyeron 201 estudios y
se analizaron once, siete de Or, dos de Sib y dos de Ri. Se obtuvo información del diseño del estudio, el tiempo de intervención,
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el número de participantes, la edad, el índice de masa corporal
(IMC), la pérdida de peso, la diferencia entre GI vs placebo,
el nivel de significancia y la calidad metodológica.
Hallazgos: El porcentaje de pérdida de peso al final de la
intervención con orlistat osciló entre 5% y 12%, un promedio
de pérdida de 8 kg y una diferencia entre GI vs placebo de 3.7
kg. Con sibutramina, entre 4% y 10%, el promedio de pérdida
de peso fue de 7.4 kg y diferencia entre GI vs placebo de 5.5kg.
Con rimonabant, se observó en promedio 7.3  kg de pérdida
de peso a los 2 años, y una diferencia con el grupo placebo
de 4.4 kg. El porcentaje de pérdida de peso fue de 7%.
Conclusiones: La pérdida de peso con farmacoterapia es
modesta, la recuperación posterior a la interrupción del trata-
miento, los efectos adversos, el costo y la falta de evidencias
sobre morbi-mortalidad a largo plazo, no justifican el trata-
miento farmacológico generalizado de la obesidad.
 Palabras clave: Orlistat; Sibutramine; Rimonabant;
Obesidad; Farmacoterapia.
The rise in the prevalence of overweight and obesity
in Latin American countries has been associated to
rapid socioeconomic development, the adoption of hyper-
energetic diets - high in fat content, sedentary lifestyles,
and environmental changes during prenatal and postnatal
development, and adulthood1. Increased energetic intake
and lower caloric expenditure, due to a sedentary life-
style, promote a positive energetic balance resulting in
the augmentation of fat deposits2. The association of
obesity with chronic diseases such as type-2 diabetes,
osteoarthritis, and cardiovascular diseases results in
greater costs in health services1,3.
Drug prescription for obesity has increased as a
result of the elevated prevalence of obesity4. The latest
approved drugs for obesity treatment may be classified
into two categories:
1. Intestinal fat absorption inhibitors, such as Orlistat
(Or) that inhibits pancreatic lipase and, consequently,
about 30% of the fats ingested are not absorbed and
are eliminated through the feces, generating an
energetic deficit and thus weight loss.
2. Appetite suppressors, such as Sibutramine (Sib) that
increase satiety or thermogenesis by means of
sympathetic stimulation, generating elevated ener-
getic waste and promoting weight loss5. Rimonabant
(Ri), an antagonist of the canabinoid system CB1
receptors that promotes weight loss by suppressing
appetite was also used in the market6.
Properly designed studies suggest that long-term
effectiveness of weight reduction programs with drugs
is associated to the inclusion of life-style changes.
However, the main limitation of those studies has been
the low retention rate of participants, low statistical
significance, and the lack of intention to treat analysis.
The objective of the current study is to evaluate the
weight loss effectiveness of pharmacological treatments
with Orlistat, Sibutramine, and Rimonabant in randomized
control trials with a follow up equal to or greater than
two years. An analysis of the cost of weight loss with
pharmacological therapy at pharmacy prices in Mexico
was included.
METHODOLOGY
The authors (LMCG and RCS) conducted a review
of the articles registered in PUBMED, SCIELO, and
EBSCOHOST published in English and Spanish with
the following search data: «1999/01/01»: «2008/12/31»
and «Obesity treatment» and «Randomized controlled
trials» and «orlistat» or «sibutramine» or «rimonabant».
To analyze the long-term effect on weight loss, the
selected studies included a follow-up equal to or greater
than 24 months. The design of the study, intervention
period, number of participants, age, body mass index
(BMI), amount of weight loss, difference between the
intervention group (IG) vs. the placebo group, and
significance level were analyzed in each article. The
Jadad score was used to assess the quality of the
studies. This score gives 0-2 points when the study
furnishes a description of randomization, 0-2 points to
blinding, and 1 point when withdrawal subjects are
mentioned in the study. The score ranges from 0 points
for the lowest quality to 5 points for the highest quality7.
Each article was independently analyzed by two
researchers (LMC and RCS). The Kappa correlation
coefficient between the two researchers was 0.93.
Disagreements or inconsistencies in the analysis were
resolved by consensus. Afterwards, a final analysis was
conducted by a third investigator (AJC), resolving the
remaining disagreements. The Kappa correlation
coefficient during this phase was 0.95. The intervention
cost of each drug was estimated from maximum market
prices in Mexico during April 2008. The price of each
drug treatment was calculated from the number of pills
taken during the study period.
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 MAIN FINDINGS
This review identified 212 potential articles related to
the effectiveness of Orlistat (Or)8-14, Sibutramine
(Sib)15,16, and Rimonabant (Ri)17,18 on weight loss. A
total of 201 studies not meeting the inclusion criteria
were eliminated and only 11 were analyzed, seven for
Or, two for Sib, and two for Ri. Table 1 shows the
characteristics and results of all the studies. The
evaluation according to the Jadad score ranged from 2
to 5 points7. Most studies showed a significant difference
among groups. As the control group was not included
during the second year of intervention, it was not
possible to evaluate the difference between the IG vs.
placebo13. Nine out of eleven studies reported intention
to treat analysis 8,12,14,18. Only the study where surgery
was compared to medical treatment reported statistical
significance (>80%)13.
WEIGHT LOSS EFFECTS
Orlistat. Davidson et al.8 included 1187 individuals
in their initial single blind, 4-week initial phase with a
hipocaloric diet. The placebo lead-in period was
completed by 892 individuals, and these were randomized
for a double-blind treatment for one year with a placebo
or 120 mg of Or. After drug assessments, those who
showed treatment compliance with Or greater than
70% were randomized into three groups: 1) placebo, 2)
60 mg of Or and 120 mg of Or for a second year. Also,
those in the placebo group that showed 70% compliance
continued the same treatment for the following 52
weeks. All participants received periodic orientation on
dietary intake, behavior modification on weight loss
strategies, and seminars on weight maintenance. A total
of 403 (43%) subjects completed the two-year treatment.
The Or group showed greater retention rates. The total
weight loss at the end of the study was not specified.
The study states that the proportion of weight loss was
greater in the Or group and that weight gain at the end
of the follow-up was greater in the placebo group.
Karhunen et al.9 included 96 obese individuals in
their two-year study. All were subjected to a four-week
lead-in period that consisted of a hypo-caloric diet or
placebo. Afterwards, they were randomly assigned for
52 weeks into two groups, either placebo t.i.d. or 120 mg
t.i.d. of Or in conjunction with a mildly hypo-energetic
balanced diet. This period was followed by a double-
blind follow up for one year in combination with a weight
maintenance diet. After four groups were formed, two
groups received the same treatment for two years. The
third group received Or during the first year and a
placebo during the second year, and the fourth group
received a placebo during the first year and Or during
the second year. Throughout the study, all subjects were
counseled by dietitians on the reduction of energy intake
and who persuaded participants to perform physical
activity. A hypo-energetic diet was prescribed with a
600-kcal/day deficit and adjusted every six months to
reduce an additional 300-kcal/day without exceeding
the total 1000-kcal/day. The results revealed a weight
loss of 12% in the Or group and 5% weight loss in the
placebo group. After the two-year intervention period,
a 7 kg (p<0.001) difference between groups was
observed. Although the study clearly indicated the total
number of participants at the end of the study, the
causes of withdrawal from the study by the individuals
were not furnished. Nevertheless, the group initially
under Or treatment that was later double-blinded to
placebo regained 6 kg during the following twelve
months.
Hauptman et al.10 evaluated the efficacy of Or in
796 adult individuals. Before the experimental study
initiated, they were all subjected to a four-week single-
blind placebo lead-in period combined with a hypo-
energetic diet (5,020-kJ/day for those with weight <90
kg and 6,275-kJ/day for those with weight >90 kg). A
total of 635 individuals (80%) concluded the initial phase
of the study. Afterwards, all individual were randomly
assigned into one of three groups: 1) placebo, 2) 60 mg,
or 3) 120 mg of Or during the following 52 weeks.
During the second year, a weight maintenance diet was
included with the same treatment to prevent weight
regain. The caloric intake was increased in those
individuals who continued losing weight after 52 weeks.
Although the subjects only received nutritional guidance
at the start of the placebo lead-in period by the study
physician, dietitians were not involved in nutritional or
behavioral counseling; they only recommended for
participants to increase physical activity. The study
revealed that during the first year the percentage of
body weight was 4% for the placebo group and 8% for
the 120 mg t.i.d. Or group, with a difference between IG
vs. placebo group of 4 kg (p=0.001). At the end of the
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Table 1
Randomized controlled trials using Orlistat, Sibutramine, or Rimonabant
IT: Intervention time; WP: Weight loss; PG: Placebo group; OG: Orlistat group; LSC: Life style changes; TID: Three times a day;
HD: Hipocaloric diet; NA: Not available, VLCD: Very low calorie diet; IG: Intervention group; DM2: Type 2 diabetes; BMI: Body mass index;
¹ CT: Combined therapy: CEV+HD: Meal replacement by supplements and sibutramine 10-15 mg/day.
     Reference
Davidson et al. 19998
Karhunen et al. 20009
Hauptman et al. 200010
Rossner et al. 200011
Torgerson et al. 200412
O’Brien et al. 200613
Richelsen et al. 200714
James et al. 200015
Redmon et al. 200516
Pi-Sunyer et al. 200617
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second year, greater weight loss was observed in the
120 mg Or group with 5%, 4% for the 60 mg Or group,
and 2% for the placebo group (p=0.001). The difference
between groups was 3.3 Kg (the placebo vs. 120 mg Or)
and 2.8 kg (placebo vs. 60 mg Or), both with a statistical
significance of p=0.001. However, the retention rate at
the end of the study was 43% for the placebo group and
56% for the Or group.
Rossner et al.11  evaluated the effects of Or on
weight loss and weight maintenance in 783 individuals.
They initiated with a four-week lead-in period that
included a balanced diet with a 600-kcal/day deficit.
Individuals with 75% compliance to the diet were
included for the following phase of the study. A total of
729 individuals  were randomly assigned into three
groups for the following 52 weeks: 1) placebo t.i.d., 2)
60 mg Or t.i.d., or 3) 120 mg Or in combination with the
same hypo-energetic diet. They continued with the
same diet during the second year and adjustments were
made according to weight loss. At the end of the two
years, the weight loss with the placebo was 4.5%, with
60 mg Or it was 6.8% (p=0.012), and with 120 mg Or
Table 1
Randomized controlled trials using Orlistat, Sibutramine, or Rimonabant (continuation)
IT: Intervention time; WP: Weight loss; PG: Placebo group; OG: Orlistat group; LSC: Life style changes; TID: Three times a day;
HD: Hipocaloric diet; NA: Not available, VLCD: Very low calorie diet; IG: Intervention group; DM2: Type 2 diabetes; BMI: Body mass index;
¹ CT: Combined therapy: CEV+HD: Meal replacement by supplements and sibutramine 10-15 mg/day.
     Reference
Davidson et al. 19998
Karhunen et al. 20009
Hauptman et al. 200010
Rossner et al. 200011
Torgerson et al. 200412
O’Brien et al. 200613
Richelsen et al. 200714
James et al. 200015
Redmon et al. 200516
Pi-Sunyer et al. 200617
Van Gaal et al. 200818
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Very low calorie diet,500-550kcal/
day during 12 weeks
Very low calorie diet (600-
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5% weight loss
DM2 patients
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22
Colombia Médica                  Vol. 41 Nº 1, 2010 (Enero-Marzo)
it was 7.8% (p<0.001). The difference between groups
was 2.5 kg (placebo vs. 60 mg Or) and 3.3 kg (placebo
vs. 120 mg Or). The retention rate at the end of the study
was 60%. A retention of 65% was observed in the 120
mg Or group.
Torgerson et al.12 in a four-year intervention study,
evaluated the efficacy of Or on weight loss in 3,305
individuals. A 800 kcal deficit diet was prescribed and
adjusted every 6 months according to weight loss.
During the first six months, nutritional counseling was
provided every two weeks and every month thereafter,
and individuals were encouraged to increase physical
activity. At the end of the fourth-year follow-up, the
difference between the IG vs. the placebo group was
2.8 kg (p=0.001) and a total weight loss of 5.25% in the
Or group and 2.7% in the placebo group. The retention
rate at the end of the study was 52% for the Or group
and 34% for the placebo group.
O’Brien et al.13 randomly assigned 40 adult individuals
to lap gastric band and 40 individuals to a nonsurgical
weight loss program that included an intensive 12 week
program that included a 500-550 kcal/day diet.
Afterwards, they were subjected to a four-week
transition program with a combination of a very low
calorie diet and 120 mg of Or t.i.d. The last phase of this
same group consisted of a combination of a hypo-
energetic diet and the same Or dosage. Considering a
requirement of at least 72 subjects to fulfill a statistical
significance of 80%, 80 individuals were included in the
study. A nutritional diet and increments of physical
activity were encouraged for all participants. During the
intensive phase, each individual was clinically evaluated
every two weeks and every six weeks afterwards.
Ninety-eight percent retention was observed in the
surgical group and 83% in the Or group. The weight
difference between groups was 15.2 kg with p<0.001.
The weight loss for the surgical group was 22% and 6%
in the Or group.
Richelsen et al.14 conducted a study with 383
individuals and in the initial eight-week lead-in period a
very low calorie diet (VLCD) was prescribed. A weekly
follow up was carried out by a dietitian. A loss of at least
5% of initial weight was required for eligibility to the next
phase. Eighty one percent (309) of the individuals were
randomized to placebo or 120 mg Or t.i.d. for the
following three years in combination with a 600 kcal
restrictive caloric diet. During the first 18 months, all
subjects were monitored every month and every three
months thereafter. All were encouraged to increase
physical activity. After the eight-week lead-in period
with a very low balanced diet, the results of the study
showed a weight loss of 14.3±2 kg in the Or group and
of 14.5±2.1 in the placebo group. The percentage of
weight loss at the end of the study was 8.3% and 6.4%
for the Or and placebo group, respectively (p<0.05).
The difference between groups was 2 kg. At the end of
the study, the retention rate was 63% for the placebo
group and 67% for the intervention group. Statistical
significance and intention to treat analysis was not
reported.
Sibutramine. James et al.15 evaluated in a double-
blind study the efficacy of Sib on weight maintenance
after a period of weight loss. During the first six months,
605 individuals initiated with a 600 kcal/day diet deficit.
Seventy seven percent (467) of the individuals that
accomplished a >5% weight loss were included in the
following phase of the study. They were randomly
assigned into two groups: 1) placebo and 2) those
treated with Sib 10-20 mg/day. During the period of
intervention, both groups received nutritional guidance
every month. The results showed a 10% weight loss in
the Sib group and a group difference of 5.5 kg compared
to the placebo group (p<0.001). The retention rate was
49% in the placebo group and 57% in the Sib group. This
study received the highest Jadad score (Table 1).
Redmon et al.16 conducted a study to evaluate the
weight loss effect of Sib in 61 individuals with type-2
diabetes. One group received combined therapy (CT)
that consisted of Sib, lifestyle changes, hypo-caloric
diets, and meal replacement by supplements; another
group received a standard therapy (ST) that consisted of
lifestyle changes combined with a hypo-caloric diet
during a one-year period. During the second year, the
ST group was prescribed the CT and the initial CT group
continued with the same treatment. At one year of
intervention, a significantly greater loss of weight was
observed in the CT group. At the end of the study, the
average weight reduction in the CT group was 4%. A
significant weight loss between groups, 8 kg in the CT
group (p<0.001) and 5 kg in the SR/CT group (p=0.001),
was found. A total of 48 individuals ended the study, 23
in the CT group and 25 in the ST/CT. However, a 24-
month follow up was not done with the ST group. In the
CT group, weight regain was observed after ten months
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of intervention and more than half of the initial weight
lost was regained at the end of the 24 months.
Rimonabant . Pi-Sunyer et al.17 conducted a double-
blind study and included 3,500 individuals of which 3,045
(87%) met the four-week lead-in period with a 600 kcal/
day deficit diet. These individuals were randomly assigned
into three groups: 1) placebo, 2) 5-mg/day of Ri, and 3)
20-mg/day of Ri. A caloric-restricted diet and guidance
on physical activity were included during the two-year
follow up. The results showed a weight loss difference
of 0.8 kg (p=0.02) between the placebo and the 5 mg/
day Ri group, and a difference of 3.5 kg (p<0.001)
between the placebo and the 20 mg/day Ri group.
During the two-year follow up, 40% of the individuals
treated with Ri achieved a >5% weight loss and 17%
achieved a weight loss of >10%. Furthermore, the
placebo group showed that 19% lost >5% of the initial
weight and 8% had a weight loss of >10% of the initial
weight.
In a double-blind study conducted by Van Gaal et
al.18 1507 individuals were included in a four-week lead-
in period with a placebo and a hypo-caloric diet.
Afterwards, all subjects were randomized into one of
three groups: 1) placebo, 2) 5 mg Ri, and 3) 20 mg Ri for
the following two years. During the first month, all
participants were scheduled for visits every 14 days and
every 28 days thereafter. At the end of the two-year
follow up, 886 individuals ended the study (58%). The
weight loss in the intention to treat was 1.2 kg in the
placebo group, 2.9 kg in the 5m Ri group, and 5.5 kg in
the 20 mg Ri group. Forty four percent of the individuals
in the 20 mg Ri group achieved a weight loss greater
than 5% of the initial weight, compared to 30% of those
treated with 5 mg Ri and 16% of those treated with a
placebo. Eleven percent of the individuals treated with
20 mg Ri achieved a weight loss >10% of the initial
weight compared to 22% of those treated with 5 mg Ri
and 6% treated with a placebo.
Adverse efects. Gastrointestinal side effects have
been described on 26% of the individuals who have used
Or on weight reduction programs and the most common
are: fecal urgency, increase on fecal depositions, fecal
incontinency and flatulency, forcing many patients to
suspend the treatment15. The most reported side effects
with Sib use are infections (22%), flu-like symptoms
(14%), headaches (14%), appetite increase (14%),
pharingitis (13%), dry mouth (9%), constipation (9%),
hypertension (8%), insomnia (8%), abdominal pain (8%),
back ache (8%), exanthema (7%), asthenia (7%), nausea
(7%), depression (6%), and other less frequent
symptoms 16. Due to the side effects of Sib on blood
pressure and cardiac frequency, constant medical
evaluation is recommended.
The most common reported side effects with Ri use
are upper airway infections (19%), rhinopharingitis
(17%), nausea (11%), arthralgias (9%), flu infections
(9%), anxiety (6%), back ache (6%), insomnia (6%),
dizziness (6%), viral gastroenteritis (6%), depression
(5%), diarrhea (5%), and other less frequent symptoms.
Nevertheless, frequent psychological evaluations are
recommended to avoid tragic effects. A high percentage
of suicidal thoughts have been described in susceptible
individuals 18.
Costs. According to prices at drug stores in Mexico
during 2008, the total expenses on a two-year treatment
would be as follows: 1) $ 4,500 dollars with 120 mg Or
three times a day, 2) $5,300 dollars with Sib 20 mg/day,
and 3) $4,100 dollars with Ri 20 mg/day. With the
minimum wage in Mexico, that cost would be equivalent
to 850 to 1100 working days19. Evaluations and
counseling by a physician, a nutritionist or a dietist, a
psychologist, a physical activity trainer, lab and X-ray
exams should also be added to the drug costs . In terms
of the costs of each kg of weight lost, with the use of
each drug it would be $750 dollars for Ri, $1,000 dollars
for Sib, and $1,200 dollars for Or.
DISCUSSION
According to the criteria used on this systematic
review, 11 randomized studies with a follow-up equal or
greater than two years were found. Seven with Or8,14,
two with Sib15,16, and two with Ri17,18. At the end of the
intervention program with Or, the average weight loss
was between 5 and 12% with Or and the longest follow-
up study was conducted in four years; the percentage of
weight loss observed was 5%12. Between 4 and 10% of
the initial weight was lost with the use of Sib15,16. These
reported weight losses are similar to those observed in
randomized controlled trials with a combination of diet
and behavior-modification techniques20.
All studies showed a low-percentage retention rate
and a significant group of individuals did not lose any
weight. The moderate response to drugs is similar to
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other diet-only studies and behavior modification
techniques; this might be due to genetic determined
factors or to imprinting during the prenatal and the first
years of life, to suppressed thermogenesis, or to an
obesogenic environment. Although a modest weight
reduction was observed, all studies showed a significant
weight reduction compared to the placebo group.
Randomization was carried out after a caloric
restriction period in 8 of the 11 studies. This indicates
that the subjects included in each study were not
representative of the general population. They were
individuals able to follow a diet regime and their responses
were ponderal to this restriction8,11,14,15,17,18. Only one
study did not include a diet therapist to offer nutritional
counseling, encourage physical activity, or prescribe
restricted diets10. The statistical power was reported in
only one study that compared medical treatment with
surgical treatment13.
The results of this review are similar to those observed
in numerous reviews and methanalysis by other authors,
including interventions by means of behavior-modification
techniques20. In general, short-term weight reduction is
observed with medical treatment along with a tendency
to regain the weight once the treatment is suspended.
Nevertheless, there have been no reports on the follow-
up time on which the weight lost is completely regained.
This may be explained by the follow-up period, which
has not been longer than four years and the low retention
rate. In addition, the secondary effects have not been
evaluated after four years with Or, two years with Sib,
or two years with Ri. Most studies have included obese,
white women without cardiac, renal, liver, and gastro-
intestinal illnesses, as well as neuro-psychological
diseases . On the Sib studies, hypertensive individuals
were excluded, and on the Ri study individuals with
neuro-psychiatric diseases were also excluded.
It is worth mentioning that a limitation to this review
is the inclusion of studies conducted after 1999 and a
follow-up greater than two years. In addition, the
policies used by some researchers and editors may
lead to a misleading conclusion, given that these
individuals put aside publications where observed
differences are not significant; also, there is no data-
base that includes all randomized trials including those
stopped due to high drop out rates or side effects.
In conclusion, the results of this review indicate that
due to observed long-term weight loss, weight regain
after pharmacological treatment, described side effects,
costs, and lack of morbi-mortality evidence after four
years, pharmacological treatment for obesity is not
justified. Although it might be prescribed in specific
cases where short-term weight reduction is mandatory
due to medical reasons.
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